NBI 69733

Drug Profile

NBI 69733

Latest Information Update: 28 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Neurocrine Biosciences
  • Class Erectile dysfunction therapies
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Erectile dysfunction; Female sexual dysfunction

Most Recent Events

  • 07 Jul 2006 No development reported - Phase-II for Erectile dysfunction in USA (unspecified route)
  • 07 Jul 2006 No development reported - Phase-II for Female sexual dysfunction in USA (unspecified route)
  • 20 Jan 2005 Phase-II clinical trials in Erectile dysfunction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top